A growing number of states are looking to set up prescription drug affordability review boards to reel in soaring prescription drug prices. In most cases, the proposed boards would allow the states to set pricing caps for certain higher-cost drugs, as well as limit price increasing by drug makers. Yet, contrary to expectations, a new […]
ACI joined 74 other groups urging Congress and the President not to adopt drug price controls. You can read the letter online.
It is no secret that the cost of prescription drugs is a major concern for Americans today. Around 79% of the public agree that the price of prescription medication is unreasonable. But while much attention is focused on the role of drug manufacturers, a new report details how almost half of consumer spending on brand-name […]
Senate Russell Office Building Featured Keynote Speaker: John Fund Topic: Escalating drug prices are generating a fierce political and policy debate. Join the American Consumer Institute on September 25th for a distinguished panel of experts who will discuss recent proposals put forth in Congress and the White House to address increasing prescription drug costs. Hear […]
Recently, some members of Congress and officials at the Department of Health and Human Services have championed a particular strategy to address this problem: pegging U.S. drug prices to what other countries pay for the same medicines. This op-ed, published in the Morning Consult, explains why putting our drug market at the mercy of what bureaucrats […]
Policymakers should reject efforts to tether U.S. drug prices to an international index. Though consumers may benefit from price reductions in the short-term, such a policy in the long run would shrink patient access to life-saving medicines, slash pharmaceutical R&D, and undermine the IP rights of American companies. This op-ed is available in Inside Sources.
In every sector of the economy, transparent pricing ensures the survival of the most efficient firms and results in lower prices as firms compete for market share. There’s no reason to think the PBM industry is an exception. To read this op-ed, visit The Hill.
As the new legislative session begins, Congress should demand increased transparency, require flow-through of manufacturer rebates to lower consumer prices, prohibit clawbacks, and consider giving federal agencies expanded oversight responsibilities to monitor PBMs’ practices. This op-ed explains why.
A group of 29 nonprofit organizations filed a letter with the FDA calling on them to foster the development of a robust biosimilars market, which would ultimately reduce prescription drug costs and provide patients with access to more affordable therapies. The letter is available online.
Earlier this year, the House removed a bipartisan generic drug measure from an act approving the federal budget. The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act is pro-consumer legislation. CREATES gives generic drug makers sufficient paid access to enough samples of the patent drug that they need to complete formal FDA equivalency […]